What is SpyBiotech?
Founded in 2017, SpyBiotech operates as a spin-out from the University of Oxford, focusing on a novel vaccine platform that utilizes a unique protein-tagging system. This technology allows for the rapid development of vaccines by enabling the precise attachment of antigens to virus-like particles. The company's market position is defined by its ability to address high-unmet medical needs, including cancer and chronic diseases, through a modular and scalable platform. By bridging the gap between academic research and commercial application, SpyBiotech has established itself as a high-authority player in the life sciences ecosystem, attracting significant interest from institutional investors and venture capital firms alike.
How much funding has SpyBiotech raised?
SpyBiotech has raised a total of $37.5M across 2 funding rounds:
Angel/Seed
$5M
Series A
$32.5M
Angel/Seed (2017): $5M with participation from GV and Oxford Sciences Innovation
Series A (2021): $32.5M led by Future Fund, GV, Oxford Sciences Innovation, and Braavos Investment Advisers
Key Investors in SpyBiotech
GV
GV is a venture capital firm founded in 2001 that invests across multiple stages and sectors, focusing on enterprise solutions, life sciences, and frontier technology innovations.
Oxford Sciences Innovation
Oxford Science Enterprises is an independent investment company created in 2015 to build transformational businesses via a unique partnership with the University of Oxford.
Future Fund
Future Fund was established in 2006 to invest for the benefit of future generations of Australians, managing public sector assets to ensure long-term financial stability.
What's next for SpyBiotech?
With the recent influx of $32.5M, SpyBiotech is well-positioned to transition from a research-heavy entity to a clinical-stage enterprise. The strategic roadmap likely involves accelerating the development of its lead vaccine candidates and strengthening its intellectual property portfolio. As the company scales, it will focus on establishing key partnerships within the pharmaceutical industry to validate its platform across diverse therapeutic areas. The continued support from its core investor base suggests a long-term commitment to building a sustainable, high-impact biotechnology firm capable of delivering transformative medical solutions to global markets.
See full SpyBiotech company page
